Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Combating Multidrug-Resistant Gram-Negative Bacteria in Africa through Diagnostic and Antimicrobial Stewardship

Project description

Improved diagnostics to combat superbugs

In sub-Saharan Africa, drug-resistant infections pose a significant challenge, exacerbated by the scarcity of life-saving antibiotics and inadequate diagnostic capabilities. While multidrug-resistant Gram-negative bacteria cause sepsis and other deadly infections, hospitals in the region rarely identify the specific pathogens. In this context, the EU-funded ComBac-Africa project is working in Côte d’Ivoire, Guinea-Bissau, and Nigeria to improve microbiological diagnostics. Specifically, it will map the spread of bacteria across people, animals, and the environment, and introduce stewardship tools to guide treatment. Crucially, the project aims to ensure equitable access to newer antibiotics, such as ceftazidime-avibactam and cefiderocol, through local capacity building and clinical trials, helping doctors treat the right bug with the right drug.

Objective

Antimicrobial resistance is a major global health threat for humans, animals and the environment, with the highest mortality and morbidity rates in sub-Saharan Africa (SSA). The World Health Organization prioritised several carbapenem- and third-generation cephalosporin-resistant Gram-negative bacteria such as Enterobacterales as the most critical pathogens with only very limited treatment options. Bacteraemia, sepsis and other severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) give rise to excess mortality. Yet, the causative pathogens are rarely identified in patients in SSA due to a lack of microbiological diagnostics. Carbapenems and the new antibiotics ceftazidime-avibactam, cefiderocol and aztreonam-avibactam are active against different MDR GNB and could significantly reduce morbidity and mortality, but they are not widely available in SSA.

The ComBac-Africa consortium has the overall goal to improve the management of severe infections due to MDR GNB in Côte d’Ivoire, Guinea-Bissau and Nigeria through the establishment of a needs-adapted diagnostic and antimicrobial stewardship (AMS) programme that provides equitable access to these novel antibiotics for targeted treatment. This will be achieved through (1) provision of high-quality and accurate microbiological diagnostics for prompt and correct identification of causative agents in bacteraemia and other severe infections; (2) a comprehensive One Health assessment of the epidemiology of GNB in humans, animal and environmental specimens; (3) tailored AMS initiatives, including early outbreak detection and infection prevention measures, to optimise the use of novel antimicrobials; (4) development of clinical algorithms for targeted diagnosis and treatment of infections due to MDR GNB; and (5) establishment of sustainable and affordable access to these antibiotics in SSA. A clinical trial will assess and quantify the impact of this multi-pronged intervention on patient outcome.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2024-01-two-stage

See all projects funded under this call

Coordinator

UNIVERSITAT DES SAARLANDES
Net EU contribution
€ 2 575 000,00
Address
CAMPUS
66123 Saarbrucken
Germany
Region
Saarland Saarland Regionalverband Saarbrücken
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 575 000,00

Participants (8)

Partners (3)